BioGeneriX AG and Neose Technologies, Inc. to Host Conference Call to Present GlycoPEG-GCSF Phase I Data

MANNHEIM, Germany & HORSHAM, Pa.--(BUSINESS WIRE)--BioGeneriX AG, a member of the ratiopharm Group of companies, and Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that they will host a conference call on Wednesday, November 7, 2007 at 8:00 a.m. (EST) to present data from two Phase I clinical studies of GlycoPEG-GCSF, comprising both ascending- and fixed-dose studies versus Neulasta®. The call is expected to last approximately 30 minutes and will include prepared remarks by Neose and BioGeneriX with a subsequent question and answer period. A slide presentation of the data will be available via the webcast.